Sarah Bennett
Jonas Salk was a physician and medical researcher who developed the first successful polio vaccine in 1955. Despite the vaccine being calculated to be worth $7 billion, he chose not to patent it, instead preferring it to be affordable and distributed as widely as possible. This decision meant that Salk did not receive any money for his discovery, which has been hailed as a miracle.
| Characteristics | Values |
|---|---|
| Did Jonas Salk receive money for his vaccine? | No, he did not receive any money for his vaccine. |
| Reason for not receiving money | Jonas Salk did not patent his vaccine, which means he lost out on an estimated $7 billion. |
| Reason for not patenting the vaccine | Salk wanted his vaccine to be affordable for all people. |
| Funding for the vaccine | The vaccine was funded by charitable donations from the March of Dimes, as well as funding from the National Foundation for Infantile Paralysis. |
Explore related products
What You'll Learn
Jonas Salk's development of the polio vaccine
Jonas Salk is credited with creating the first effective vaccine against poliomyelitis, commonly known as polio. Born in New York City in 1914, he was the first member of his family to attend college, graduating from the New York University School of Medicine in 1939.
Salk began his career as a scientist physician at Mount Sinai Hospital, where he worked with Thomas Francis Jr. to develop an influenza vaccine. In 1942, he joined Francis at the University of Michigan School of Public Health on a research fellowship. By 1947, Salk had become the director of the Virus Research Laboratory at the University of Pittsburgh School of Medicine, where he began to focus on poliovirus research.
In 1948, Harry Weaver, the director of research at the National Foundation for Infantile Paralysis, contacted Salk and asked him to determine the number of poliovirus types. At the time, only three types were known, but Weaver believed there could be more. With funding and support from the Foundation, Salk devoted the next seven years to developing a vaccine against polio.
Salk's approach was to use a "killed" virus, which he believed could immunize without risking infection in the patient. He first tested the vaccine on himself, his family, and volunteers who had not had polio. All developed anti-polio antibodies and experienced no negative reactions. In 1952, Salk and his team successfully tested the vaccine on monkeys, and the following year, they reported the results of vaccinations in more than 100 adults and children.
In 1954, national testing began on one million children, who became known as the Polio Pioneers. On April 12, 1955, the results were announced: the vaccine was safe and effective. The federal government immediately implemented a plan to distribute the vaccine to children across the country. Within a year, deaths attributed to polio had declined by 50%, and by 1962, the average number of polio cases in the US had dropped from over 45,000 to 910.
Despite the immense success and value of his vaccine, estimated at $7 billion, Salk chose not to patent it or seek any profit from it. He preferred that it be distributed as widely as possible to benefit mankind.
Vaccines: Immune System Superpowers Explained
You may want to see also
Explore related products
Salk's reasons for not patenting his vaccine
Jonas Salk did not patent his polio vaccine, and his discovery was donated for the benefit of mankind. When asked by Edward R. Murrow who owned the patent to the polio vaccine, Salk replied, "Well, the people, I would say. There is no patent. Could you patent the sun?"
Salk's inactivated polio vaccine came into use in 1955. It is on the World Health Organization's List of Essential Medicines. Salk preferred not to have his career as a scientist affected by too much personal attention, as he had always tried to remain independent and private in his research and life. However, this proved to be impossible.
Salk's vaccine was calculated to be worth $7 billion had it been patented. However, lawyers from the National Foundation for Infantile Paralysis did look into the possibility of a patent, but ultimately determined that the vaccine was not a patentable invention because of prior art. The foundation that funded the research also played a role in the decision not to patent. The public voluntarily funded the vaccine's incredibly expensive research and field testing.
Salk's philosophy and way of life also played a role in the decision not to patent the vaccine. He campaigned vigorously for mandatory vaccination throughout his life, calling the universal vaccination of children against disease a "moral commitment".
Hepatitis Vaccine: A Two-Part Series for Protection
You may want to see also
Explore related products
The financial loss Salk incurred
Jonas Salk did not patent his polio vaccine, which was declared safe and effective in 1955. He wanted it to be affordable for all people and as a result, he lost an estimated $7 billion.
Salk's vaccine was composed of "killed" polio viruses, which could immunize without the risk of infecting the patient. This was contrary to the prevailing scientific opinion at the time, which believed that effective vaccines could only be developed with live viruses. In fact, many researchers, including Polish-born virologist Albert Sabin, called Salk's approach dangerous. Sabin was developing an oral "live-virus" polio vaccine at the same time and even belittled Salk as "a mere kitchen chemist".
Salk's decision not to patent the vaccine meant that he did not receive any money for his discovery. The vaccine was funded by charitable donations raised by the March of Dimes, and Salk felt that it should be distributed as widely as possible. He stated in an interview: "There is no patent. Could you patent the sun?"
The financial loss incurred by Salk is estimated to be $7 billion. This is based on the calculation that the cost of the vaccine would have increased by 25% if patent licensing costs had been included. Additionally, the oral polio vaccine, which is the type widely used today, is cheaper to produce than Salk's intravenous vaccine, which would have cost $2.2 extra per child to administer.
Immunization vs Vaccination: What's the Difference?
You may want to see also
Explore related products
Funding sources for Salk's vaccine trials
Jonas Salk was an American virologist and medical researcher who developed one of the first successful polio vaccines. He did not patent the vaccine and did not earn any money from his discovery, preferring it to be distributed as widely as possible. It is estimated that he would have been $7 billion richer if he had patented the vaccine.
Salk's work on the polio vaccine was funded by the National Foundation for Infantile Paralysis (NFIP), later renamed the March of Dimes. The NFIP was a grassroots organisation devoted to raising money to fund the care of polio victims and research for a cure. The foundation funded Salk's recruitment to the University of Pittsburgh and completely oversaw and funded the 1954 Field Trials, which were the largest clinical trial in history with 1.8 million children recruited as participants. The trial was so large that it required over 300,000 volunteers to carry out the process.
The NFIP's funding came from donations from the American public, including millions of charitable donations raised by the March of Dimes. The foundation's lawyers had investigated the possibility of patenting the vaccine, but ultimately determined that it was not a patentable invention due to prior art and Salk's reluctance to pursue a patent.
In addition to the funding from the NFIP, Salk also secured grants from the Mellon family, which allowed him to build a working virology laboratory. He also had support from the University of Pittsburgh, where he was a professor and conducted his polio research.
California Vaccine Lottery: How to Enter and Win
You may want to see also
Explore related products
![EvolveFISH Jonas Salk Science Poster - [11'' x 17'']](https://m.media-amazon.com/images/I/71q+pI0y9vL._AC_UL320_.jpg)
The impact of Salk's vaccine
Jonas Salk was an American virologist and medical researcher who developed one of the first successful polio vaccines. He did not patent the vaccine, famously stating, "Could you patent the sun?", and as a result, he did not earn any money from his discovery. It is estimated that Salk lost out on $7 billion by choosing not to patent his vaccine.
The introduction of the Salk polio vaccine is considered one of the most important events in translational science. The vaccine was based on a "'killed' poliovirus, which Salk believed could immunize without the risk of infecting the patient. This approach was safer and simpler to produce than vaccines that used live or weakened viruses.
The development of the Salk vaccine was funded by the National Foundation for Infantile Paralysis (now known as the March of Dimes Birth Defects Foundation). The vaccine underwent rigorous testing in one of the largest clinical trials in history, with nearly 2 million children participating. In 1955, it was announced that the vaccine was both safe and effective, leading to celebrations across the nation.
The impact of the Salk vaccine was significant. In the two years before the vaccine was widely available, the average number of polio cases in the United States was more than 45,000. By 1962, that number had dropped to 910. Worldwide, polio cases have fallen by more than 99% since the vaccine's introduction, and the disease is on the verge of eradication. Less than 25 years after the release of Salk's vaccine, domestic transmission of polio had been eliminated in the United States.
The success of the Salk vaccine highlights the importance of global vaccination efforts in preventing disease and protecting public health. It also serves as a reminder of the power of science and collaboration in safeguarding humanity.
Wakefield's Vaccine Patent: A Conflict of Interest?
You may want to see also
Frequently asked questions
No, Jonas Salk did not receive any money for his polio vaccine. He did not patent his vaccine so that it would be affordable for everyone.
Jonas Salk lost an estimated $7 billion by not patenting his polio vaccine.
Jonas Salk did not patent his vaccine because he wanted it to be distributed as widely as possible. He also believed that it would be affordable for everyone if it was not patented.
Yes, Jonas Salk received funding from the National Foundation for Infantile Paralysis (later renamed the March of Dimes Foundation) for his vaccine trials.
Jonas Salk's polio vaccine was developed using a killed-virus. This method involved growing samples of the virus and then deactivating them by adding formaldehyde so that they could no longer reproduce. This technique was contrary to the prevailing scientific opinion at the time, which believed that effective vaccines could only be developed using live viruses.
